<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess the biological significance of vascular endothelial growth factor (VEGF) A, VEGF receptor (Flk-1) and cyclooxygenase 2 (COX2) expression with respect to microvessel density (MVD), proliferative activity (Ki-67), expression of p53 and clinical presentation in a large cohort of nodal B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: An immunohistochemical and morphometric study was performed on a validated tissue microarray containing 271 B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> specimens, 197 of which included follow-up data </plain></SENT>
<SENT sid="2" pm="."><plain>Statistical assessment was done by Pearson's chi(2) test, Spearman's rank correlation coefficient, analysis of variance and survival analysis </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: 266 (98%) cases were evaluable </plain></SENT>
<SENT sid="4" pm="."><plain>Strong VEGF expression was observed in only 20 diffuse large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Flk-1 and COX2 were expressed in 53 and 21 cases, respectively, mainly in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) grade 3 and mantle cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCLs</z:e>), in a low proportion of cells </plain></SENT>
<SENT sid="6" pm="."><plain>MVD decreased in the following order: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>, FLs, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCLs</z:e> and small lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>/<z:hpo ids='HP_0011010'>chronic</z:hpo> lymphocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLLs) </plain></SENT>
<SENT sid="7" pm="."><plain>VEGF expression correlated with Ki-67, p53 and COX2 expression in the whole cohort and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Flk-1 expression correlated with Ki-67 in the cohort and in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL and FL grade 1 and 2 </plain></SENT>
<SENT sid="9" pm="."><plain>COX2 expression correlated with Ki-67 and p53 </plain></SENT>
<SENT sid="10" pm="."><plain>The analysed <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> parameters did not correlate with clinical parameters or survival </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> plays a differential role in various B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> express the potential molecular therapeutic targets VEGF and COX2, and have higher MVD </plain></SENT>
<SENT sid="13" pm="."><plain>In a few low proliferation-fraction <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, Flk-1 might have a role in proliferative advantage </plain></SENT>
<SENT sid="14" pm="."><plain>Therapeutic strategies aimed at <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> should take into account <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> </plain></SENT>
</text></document>